About: MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.30 (+4.00%)
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
30 Apr, 1:51 am GMT+0
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Market cap
N/A
NYSE rank
N/A
Sector Rank
N/A
Delayed
30 Apr, 1:51 am GMT+0
MAIA Market Signals